<DOC>
	<DOCNO>NCT00261612</DOCNO>
	<brief_summary>Mantle cell lymphoma ( MCL ) remain difficult treat standard treatment approach . Novel drug show promising result early clinical evaluation . In current trial , investigate combination bortezomib ( proteasome inhibitor ) , rituximab ( monoclonal antibody ) , dexamethasone patient MCL , already pretreated standard chemotherapy show sign disease progression . The study objective include remission rate , safety drug combination , survival time .</brief_summary>
	<brief_title>Bortezomib , Rituximab Dexamethasone ( BORID ) Relapsed/Refractory Mantle Cell Lymphoma</brief_title>
	<detailed_description>Description treatment regimen : Bortezomib : 1.3 mg/m2 i.v . bolus injection , give day 1 , 4 , 8 , 11 treatment cycle ; Rituximab : 375 mg/m2 infusion , day 1 cycle ; Dexamethasone : 40 mg per day orally ( day 1 â€“ 4 ) treatment cycle . Treatment give total 6 cycle ( every 21 day ) , follow maintenance treatment rituximab ( 375 mg/m2 every two month 4 time )</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>mantle cell lymphoma stage II IV , previously treat least one line prior therapy ( CHOP CHOPlike ) , measurable disease , age 19 75 year , adequate cardiac , liver renal function test , patient 's write informed consent second malignancy , evidence CNS involvement , clinically significant peripheral neuropathy ( grade II high ) , HIV positivity , pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>relapse chemotherapy-refractory disease</keyword>
</DOC>